Skip to content
Company Analysis

Neurocrine Biosciences, Inc. NBIX

A comprehensive view of key metrics, scores, and financial health for Neurocrine Biosciences, Inc.

Overview of Neurocrine Biosciences, Inc.

NBIX NMS
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Large Cap
Neurocrine Biosciences, Inc. (NBIX), is a Large Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $159.76, about 59.8% overvalued vs fair value, +28.4% 1Y return, placing in the top 25% of its sector.
Metrics P/E 30.4× Rev Growth 21.5% ROE 16.4% Gross Margin 98.2%
USD 159.76
-1.81%
(Delayed)
• Vol 90d: 35.8%
52-Week Range
Market Cap
$16.36B
Enterprise Value
$15.30B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Excellent
Health
Fair
Efficiency
Good
Valuation
Fair
Growth
Good
Profitability
Excellent
Health
Fair
Efficiency
Good
Valuation
Fair
Completeness: 82%
Confidence: 79%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.neurocrine.com
HQ San Diego, CA
Employees 2,000
Fiscal year Dec 31

Next Events

Earnings Jul 29 Estimated

Fair Value Snapshot

Bear Base Bull
$59
$64
$70
Current: $159.76 -60% vs base

Engine Room Money Flow™

Large Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$2.9B
21.4%%
Gross Profit
$2.8B
21%%
R&D Expense
$1.0B
38.9%%
Operating Income (EBIT)
$636.5M
3.9%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
123.0%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$167.7M
22.4% of FCF

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
3
Active Leaks
2/3
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Neurocrine Biosciences, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
81
/100
Strong
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
81
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 97% Coverage
Trade-Off Triangle Visualization A ternary plot showing NBIX's balance between Growth (34.4%), Profitability (36.7%), and Safety (28.9%). Growth 34% Safety 29% Profitability 37%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

77th percentile vs peers
78
Key Signals
Rev Growth YoY 21.4% 78p Revenue CAGR 3Y 24.3% 84p EPS CAGR 3Y 44.0% 93p EPS Growth YoY 41.9% 56p
Strengths
  • Revenue CAGR 3Y in top 20% of peers (24.3%, 84th percentile)
  • EPS CAGR 3Y in top 20% of peers (44.0%, 93th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Growth above peer median with strong metric coverage (90%)
Risks

No significant risks identified for this axis.

Profitability

83th percentile vs peers
83
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

65th percentile vs peers
65
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Neurocrine Biosciences, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$64.20
- - -
-59.8% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000